Natrogen Therapeutics International, Inc Report issue

For profit Phase 2
Founded: New York NY United States (2002)
Status: Defunct (2013)

Organization Overview

First Clinical Trial
2010
NCT01216280
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

tak-114 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1